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Background: Drug users suffer harm from the injecting process, and clinical services are reporting increasing
numbers presenting with skin-related problems such as abscesses and leg ulcers. Skin breakdown can lead to
long-term health problems and increased service costs and is often the first indication of serious systemic ill health.
The extent of skin problems in injecting drug users has not previously been quantified empirically, and there is a
dearth of robust topical literature. Where skin problems have been reported, this is often without clear definition
and generic terms such as ‘soft tissue infection’ are used which lack specificity. The aim of this study was to identify
the range and extent of skin problems including leg ulceration in a sample of injecting drug users. Definitions of
skin problems were developed and applied to descriptions from drug users to improve rigour.
Methods: Data were collected in needle exchanges and methadone clinics across Glasgow, Scotland, from both
current and former drug injectors using face-to-face interviews.
Results: Two hundred participants were recruited, of which 74% (n = 148) were males and 26% (n = 52) were
females. The age range was 21–44 years (mean 35 years). Just under two thirds (64%, n = 127) were currently
injecting or had injected within the last 6 months, and 36% (n = 73) had previously injected and had not injected
for more than 6 months.
Sixty per cent (n = 120) of the sample had experienced a skin problem, and the majority reported more than one
problem. Most common were abscesses, lumps, track marks and leg ulcers. Fifteen per cent (n = 30) of all
participants reported having had a leg ulcer.
Conclusions: This is an original empirical study which demonstrated unique findings of a high prevalence of skin
disease (60%) and surprisingly high rates of leg ulceration (15%). Skin disease in injecting drug users is clearly
widespread. Leg ulceration in particular is a chronic recurring condition that is costly to treat and has long-term
implications for drug users and services caring for current or former injectors long after illicit drug use has ceased.
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The skin is the largest and heaviest organ of the body
and provides protection against pathogens and aqueous,
chemical and mechanical assault, and has a role in me-
tabolism, thermoregulation, sensation and communi-
cation [1]. By injecting with a needle, the body’s main
protective barrier, the skin, is breached potentially cau-
sing harm. Illicit drug injectors repeatedly breach this
barrier and may use contaminated drugs and unsterile
equipment causing injecting injuries. A plethora of risk* Correspondence: a.f.coull@stir.ac.uk
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unless otherwise stated.factors may contribute to harm and subsequent skin
problems, such as injecting technique, the injecting mix-
ture, quantity of acid for dissolving, choice of injecting
equipment and paraphernalia, selection of injecting site,
longevity of injecting habits as well as underlying health
and social issues [2,3]. Various skin problems in drug
users have been reported such as abscesses, ulcers, track
marks and soft tissue infections [2,4-6]; however, the
published papers tend not to adequately define or ex-
plain these skin complications [7,8]. Reported skin prob-
lems are at best ill defined but more commonly grouped
together as soft tissue infections without specifying what
type of lesions or describing the injury clearly such thattd. This is an Open Access article distributed under the terms of the Creative
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studies can be made [9-12]. Of concern is the grouping
together of open wounds as ‘infections’ without identify-
ing key features of skin infection such as pain, redness,
pus and cellulitis as this may lead to inappropriate diag-
nosis and unnecessary prescribing of antibiotics [3]. Si-
milarly, positive bacterial cultures from skin lesions do
not always indicate clinical infection as most open wounds
will contain bacteria but are not necessarily infected [13].
Differentiating between types of wounds is therefore im-
portant for treatment especially where drug users tend to
attend and be treated in drug services rather than special-
ist wound centres.
The extent, or prevalence, of skin problems in the
drug-using population was previously unknown. A lit-
erature search conducted in 2012 revealed no relevant
empirical studies, so there is a dearth of evidence about
not only the magnitude of the problem but also the
short-and long-term implications of skin breakdown for
injecting drug users, although skin disease is a known
and frequent cause of morbidity in the homeless popula-
tion, many of whom are drug users [14,15]. Health care
professionals are increasingly encountering injection-
induced wounds [16-18,6,19,5] such as infections, ab-
scesses and leg ulcers in their practice, but much of the
published literature focused on skin and wound care
specifically is limited to single case reports (for example
[16,20]). Skin breakdown, whilst serious in itself, is often
the first indication of a serious systemic disease pro-
cess such as septicaemia, anthrax or necrotizing fasciitis
[21-25], so understanding the implications of injecting on
the skin is important [12,26].
Although no empirical quantitative data exists, case
studies and anecdotal reports also indicate that phle-
bitis, thrombosis and clots in the venous system oc-
cur frequently in drug users as a sequelae to injecting
[27-30,19,31,32], and lasting damage to skin, such as chro-
nic ulceration from venous insufficiency, may result. Many
users report periods of hospitalisation due to deep vein
thrombosis which damages vein valves [33,31]. Venous
disease, and post-thrombotic syndrome, may be displayed
in relatively young individuals who have been, or are, drug
injectors [28]. Chronic venous disease leads, at its end
stage, to ulceration of the skin, which, in the non-drug-
using population, tends to become long lasting and recurs
[34]. The progression of venous disease in drug users is
unknown, but it is likely to be similarly persistent and
costly [35].
Leg ulceration is arguably the most costly of injecting
injuries to the skin with long-term implications for treat-
ment and medical care. Around 1% of the general popu-
lation will suffer from leg ulceration at some point in
their lives [36]. Leg ulceration can also have an impact
on quality of life with sufferers citing pain, odour andmobility problems. Injecting drug users are seen increas-
ingly at leg ulcer clinics, but it is unknown how significant
the problem in this population is or what the long-term
sequelae may be [2,35].
The increasing numbers of case studies published
[37,38], anecdotal reports and related studies [39,5,19,18]
would indicate that the presence of skin disease in injec-
tors is becoming more prevalent or apparent which would
suggest the need for further empirical study.
Clinical observations amongst the drug-using popula-
tion in Glasgow have demonstrated a prevalence of skin
problems and leg ulceration [2], but no one appears to
have previously examined and quantified the extent of
the problem.
The aim of this study, therefore, was to identify the
prevalence of skin problems and of leg ulceration, with-
in a convenience sample of intravenous drugs users in
Glasgow.
Methods
A survey was undertaken and data were collected using
structured face-to-face interviews utilising a specially de-
signed questionnaire. The questionnaire was developed
based on knowledge of injecting habits drawn from lit-
erature and anecdotal experience and aimed to identify
likely risk and causal factors. Participants were asked
questions about their injecting habits and complications
related to skin that they had experienced during their
injecting careers. As no published definitions of injecting
wounds could be found that were comparable, defini-
tions of known skin complications arising from injecting
were developed and refined to ensure rigour based on
existing literature and clinical expertise [40,2,41]. Utilis-
ing the same researcher and the same set of definitions
ensured maximum rigour and accuracy in the reporting
of the skin problems, within the limitations of self-
report and recall. Participants were asked for clarifica-
tion of the meaning of words they used to describe
injecting injuries such as ‘abscess’ or ‘acid burn’, in
order that the same definitions were applied to the same
type of description.
The definitions were matched to descriptions from the
participant to ensure that the same definition was ap-
plied to each case (Table 1). The position of lower ex-
tremity wounds was ascertained to avoid confusion
between the reporting of foot wounds and the reporting
of leg ulcers. Previous work has recognised the import-
ance of clarity of position of wounds especially when the
term ‘ulceration’ is used which can be misunderstood
[42]. Participants who experienced skin problems were
asked further questions about the type of skin problem
they had. These were defined and explored with each
participant to ensure that a standard definition (see
Table 1) was adhered to.
Table 1 Definitions of skin problems
Skin problem Definition
Leg ulcer A break in the skin between the knee and the
ankle that remains unhealed for 4 weeks or
more (SIGN, 1998)
Lumps Hard swellings without broken skin, not red or
hot or particularly painful
Track marks Scratch marks, raised red veins, raised hardened
veins
Abscesses Raised red hot painful lumps, with or without
obvious pus/broken skin—possibly required
lancing/surgery or have spontaneously burst
Acid burns Painful, blistered or broken skin directly
attributed to use of acid
Broken skin (heals
within 4 weeks)
Injecting injury that has caused a break in the
skin, wounds or scabs that have healed in less
than 4 weeks
Chronic wounds Any break in the skin (not a leg ulcer) that has
been present 4 weeks or more
Rashes Multiple red or pink spots, raised or flat, that
last longer than the short period following
injection
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lated to injecting habits and risk factors); however, only
the prevalence data are reported in this paper.
Sample
Drug use has its own subcultures and users often edu-
cate peers within their own geographical areas, and ac-
tual injecting practices can vary from suburb to suburb.
A wide geographic sample even within one city, there-
fore, was important to ensure variations due to locality
were captured. Participants were recruited from eight dif-
ferent venues (needle exchanges and methadone clinics)
in the north, south, east and west of Glasgow. These ven-
ues were selected as they were where the highest numbers
of injecting drug users were known to engage with ser-
vices in each direction of the city and where a private
room was available for interviewing. A convenience sam-
ple was selected as this is a challenging population to
investigate because many drug users are transiently ac-
commodated, frequently incarcerated and engaged in cha-
otic lifestyles, which means arranging appointments for
interview or follow-up can be difficult or impossible, and
a sampling frame could not therefore be used [43,44,6].
The approach to recruitment was similar to that of other
local studies which had successfully overcome many of
the traditional problems of recruitment of drug users [45].
Inclusion/exclusion criteria
In Scotland alone, it is thought that the number of indi-
viduals with problem drug use is nearly 60,000. Glasgow
has the highest rate of problematic drug use in Scotland,
with prevalence rates remaining consistent in the last 5years and thought to be around 13,900 individuals. The
majority of drug users are aged between 15 and 64
years, with the greatest proportion in the 35–64-year
age group [46]. The prevalence of injecting drug use
is not currently known, although older studies have
been published [47].
The research aimed to capture people like these de-
scribed, whilst avoiding the challenges of working with
children. Participants over the age of 44 years were ex-
cluded to attempt to reduce the potential results created
by the impact of age-related disease on ulcer develop-
ment. Leg ulcer studies of a wider population will tend
to include from age 50 years of age or over [42], so 44
years was considered to be a safe margin.
The sample included individuals with a current or pre-
vious history of injecting drug use, aged 16 to 44 years,
who could understand and speak English. Participants
were excluded if they did not meet the inclusion criteria
or did not appear to be able to either understand what
they are consenting to take part in or answer questions,
including being visibly under the influence of drugs or
alcohol. Staff at the recruitment venues who were often
familiar with individual participants also helped identify
and exclude those who were not fit to consent at that
time [48].Recruitment
Posters and leaflets describing the study were displayed
in each venue for at least 2 weeks prior to recruitment
commencing. During recruitment, individuals were ap-
proached by the researcher as they entered each venue
and asked if they would be interested in taking part in a
research study and answering some questions about
injecting and complications. Informed consent was ob-
tained and the interviews lasted an average of 20 min.
A pilot study was undertaken earlier to test recruit-
ment, data collections tools and analysis which informed
the method. Ethical and governance approval was sought
and obtained from NHS Greater Glasgow and Clyde to
undertake the study.
The study was conducted over a period of 3 months at
the end of 2008.Data collection
Interviews were conducted across the eight venues in
the north, south, east and west of the city. Participants
provided initials and date of birth, together with the first
few letters of their postcode—this allowed any duplicate
interviews to be identified.
All interviews were conducted by one researcher, and
participants were given an honorarium of a £2 shopping
voucher as an acknowledgement of their time taken to
participate.
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occasions, participants who the researcher thought had
been interviewed before were adamant they had not pre-
viously been interviewed. The researcher felt obliged to
conduct a second interview. When initials and dates of
birth were checked, the three interviewees were found
to be duplicates. The participants knew of the incentive/
honorarium and may have wished to collect another £2
voucher. The data from these second three interviews
were removed from the database. A fourth interview was
abandoned midway, and the incomplete data from the
fourth interview were also removed and not included in
the analysis. The analysis was conducted on the remai-
ning 200 interviews.
Data analysis
All data were entered into SPSS version 15.0 and checked
independently for accuracy. All identifiers were removed
after checking. Data were analysed using descriptive and
inferential statistics. The confidence interval for all tests
was 95%. The data were reviewed for missing values and
there were none.
Results
Sample
As can be seen from Table 2, participants were predom-
inantly male (74%, n = 148) with 26% (n = 52) females.
The age range was 21–44 years (mean 35 years). Just
under two thirds (64%, n = 127) were currently inject-
ing or had injected within the last 6 months, and 36%
(n = 73) had last injected more than 6 months prior to
the interview.
Of the current injectors, 20% were long-term injectors
(n = 26), who had been injecting for 20 years or more.
In response to the question ‘Have you ever had a skin
problem?’, 60% (n = 120) said yes and 40% said no (n = 80).
The majority of these were male (72%, n = 86; females
28%, n = 34).
The majority of the current (63%, n = 80) and over half
of the former (55%, n = 40) injectors reported a problem
with the skin. Almost all of the long-term injectors (>20
years) reported a problem with their skin (85%, n = 22).
A Mann-Whitney U test comparing groups of those
that had injected for less than a year, 1–5 years, 6–10
years, 11–20 years and over 20 years showed that those
who injected for longer experienced more skin problems
(U = 2,896, z = −4.89, p = ≤0.001), indicating that the lon-
ger a person injects, the more likely they are to have a
skin problem.
Although 60 participants had never had skin problems,
74 (62%) of the participants reporting skin problems ex-
perienced more than one type of problem (Figure 1).
The majority of those who reported skin problems
complained of abscesses (75%, n = 90), followed by lumps(48%, n =58) and track marks (47%, n =56), followed by
leg ulcers (25%, n = 30) acid burns (24%, n = 29) and chro-
nic wounds other than leg ulcers (23%). Eight per cent
complained of other skin problems, and these were scar-
ring (n =3), bruising (n =2), varicose veins (n =2), phlebitis
(n =1), cellulitis (n =1), phlebitis (n = 1), necrotising fasci-
itis (n =1), haematoma (n =1) and thin skin (n = 1).
In response to the question ‘Have you ever had a leg
ulcer?’, 25% (n =30) of those reporting skin problems
said yes; of these, 47% (n =14) had active ulceration at
the time of the interview. Therefore, the prevalence of
active leg ulceration within the 200 participants was 7%
(14/200) and lifetime prevalence was 15% (30/200).
Eighteen per cent (n = 13/73) of the former injectors and
a total of 13% (n = 17/127) of the current injectors had
suffered leg ulceration.
A higher percentage of females had leg ulceration
(17%, n = 9/52) than men (14%, n = 21/148). Of those
with a leg ulcer, 6 ulcers had never healed, 12 ulcers had
healed up and broken down/recurred again and 12 ul-
cers had healed up at the time of the research.
Discussion
This study is the first empirical work that accurately de-
fines and matches described skin problems in injecting
users to specified terms. Drug users with skin problems
are most likely to present to services such as needle ex-
changes and drug workers in the first instance, where
staff have less expertise in the physical side of injecting
complications, such as the identification of wound infec-
tion, and the management of acute and chronic wounds.
It has therefore been difficult, until now, to empirically
determine the nature and extent of skin problems be-
cause of the diverse presentation across the sector.
The clear, but simple, definition of skin problems is
new in the field and ensures consistency and accuracy by
researchers, within the scope of participants’ recall. All
skin problems within this study were self-reported by
participants. Reassuringly, a closely relevant study by
Morrison et al. [49] compared answers from a self-report
questionnaire about injecting-related harm to clinicians’
observational findings and found consistency between the
two. Whilst the definitions were stringently applied to the
data collection, some skin problems may have been for-
gotten, or exaggerated. However, the evidence suggests
that recall is fairly accurate, even in drug users [50-52].
There was an advantage in gathering data face to face
in that the researcher was able to clarify and determine
the precise condition reported by the participants by
probing further and seeking clarification on position as
well as appearance. However, clinical examination was
not undertaken; this may have been advantageous where
there was a current skin problem but would not have as-
sisted in identifying or clarifying past problems. However,
Table 2 Summary of results
Injected within the
last 6 months (n)
Percentage Previously injected but not
in the last 6 months (n)
Percentage Total (n) Percentage
All 127 64 73 36 200 100
Gender Male 97 76 51 71 148 74
Female 31 24 21 29 52 26
200 Total
Age group (years) 20–24 7 5.5 4 5 11 5.5
25–29 23 18 6 8 29 14.5
30–34 39 31 11 15 50 25
35–39 37 29 28 38 65 32.5
40–44 21 16.5 24 33 45 22.5
200 Total
Age when started
injecting (years)
Under 16 21 16 14 19 35 17.5
16–19 29 23 28 38 57 28.5
20–24 38 30 17 23 55 27.5
25–29 25 20 7 10 32 16
30–34 10 8 7 10 17 8.5
35–39 4 3 0 0 4 2
200 Total
Length of injecting
career (years)
Less than 1 7 5.5 12 16 19 9.5
1–5 32 25 15 21 47 23.5
6–10 35 27.5 14 19 49 24.5
11–20 35 28 24 33 59 29.5
Over 20 18 14 8 11 26 13
200 Total
Individuals reporting
a skin problem
80 63 40 55 120 60
Type of skin problem Leg ulcer 17 13 13 18 30 15
Lumps 40 31 18 25 58 29
Track marks 40 31 16 22 56 28
Abscesses 58 46 32 44 90 45
Acid burns 21 17 8 11 29 15
Broken skin 15 12 10 14 25 13
Chronic wound 17 13 11 15 28 14
Rashes 2 2 1 1 3 2
Other skin problems 6 5 5 7 11 6
Some individuals reported more than one skin problem so therefore percentages may add up to more than 100%. Percentages rounded up.
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Sample
The socio-demographic profile of Glaswegian drug in-
jectors is known to be two-thirds male, typically un-
employed and aged about 30 years, and mostly usingheroin [53-55]. The sample in this study was similar in
that the majority of participants were male with a com-
parable mean age.
There were no participants under the age of 21 years,
and no one was excluded on the basis that they were too
young to participate. This may indicate that injecting in
this younger age group is low and so skin problems may
Figure 1 Number of different types of skin problems experienced.
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cruitment were not engaging with younger drug users
and so this figure may not be indicative of skin problems
in younger injectors.
Skin problems
One hundred twenty participants reported skin prob-
lems, giving a prevalence of 60%. The majority com-
plained of abscesses (75%), lumps (48%) and track marks
(47%), followed by leg ulcers (25%), acid burns (24%)
and chronic wounds other than leg ulcers (23%). Eight
per cent complained of other skin problems over the
duration of their injecting careers including bruising and
varicose veins, phlebitis, cellulitis, haematoma, scarring
and thin skin.
These findings indicate that a large proportion has ex-
perienced abscesses and soft tissue infection. This is un-
surprising given that the injection process will not be a
sterile procedure and the drugs injected are often cut
and mixed with unsterile materials; nevertheless, the
prevalence is extremely high.
Any injecting injury is frequently referred to as an ab-
scess by both service users and staff. Similarly, within
the medical literature, soft tissue/bacterial infection is
the main injecting problem described [56]. Whilst there
is no denying that infection is a common sequela to
injecting illicit materials, this is a misrepresentation of
the problem.
Traditionally, abscesses may be defined as ‘a localised
collection of pus’ [57]. However, many papers commonly
use the term abscess to describe any kind of red raised
lump. This is confusing and possibly harmful. Many
missed ‘hits’ (injections) also appear as red lumps and
can be misnamed abscesses. The injection may miss the
vein, or puncture the vein, allowing fluid to escape into
the tissues. They tend not to be pus filled, hot, or with
spreading cellulitis; however, they may take some time
to resolve but are not infected and do not require
antibiotics [58]. The abscesses may require treatment
with antibiotics, but overuse or inappropriate use ofantibiotics can lead to resistance and other unwanted
side effects [13].
However, appropriate assessment of skin problems and
injecting injuries is important as misdiagnosis can have
serious implications. Skin breakdown may be the first
sign of problematic drug use. Beeching and Crowcroft
[59], in their overview of tetanus in injecting drug users
(IDUs), warn clinicians of systemic effects of apparently
trivial wound infections in IDUs when they present with
collapse, sepsis or odd neurological symptoms which
might otherwise be dismissed as direct results of drug
intoxication. Seemingly innocuous lesions can also in-
dicate far more serious systemic disease (e.g. anthrax,
wound botulism, clostridia [60,4,61]), and skin problems
must not be viewed in isolation and should be part of a
systemic assessment of other signs and symptoms such
as fever and flu-like illness. It is normal for the body to
respond with a temporary inflammatory response to in-
jury, but what is more difficult is detecting the difference
between normal inflammation and an inflammatory pro-
cess which may indicate something more serious and
systemic occurring.
Existing guidance errs very much on the side of cau-
tion, which, although correct, demonstrates the difficulty
in differentiating between lesions, and partly why de-
finition is so important [62]. Clearer guidance is nee-
ded for both health professionals and drug users on
skin problems.
Leg ulceration
The findings revealed a high prevalence of leg ulceration
in the sample population of young injecting drug users.
Fifteen per cent of the sample population had experi-
enced a chronic leg ulcer, defined as ‘a break in the skin
between the knee and the ankle that was present four
weeks or more’ [63], whilst 7% had an active ulcer at the
time of interview. Comparatively, within the general po-
pulation, it is known that 1% of the adult populations
(within Western countries) are likely to have a chronic
leg ulcer at some time [64]. Later studies have agreed
with this figure [65,66], and therefore, the prevalence of
leg ulceration within an injecting population is worry-
ingly high. This figure, of 15% prevalence, verifies the
anecdotal claims from community nursing practitioners
who are seeing rising numbers of young people with leg
ulceration in their clinical practice but have little em-
pirical evidence to support their assertion [67].
This finding is of concern as once ulceration occurs,
the long-term impact on health services may become
onerous. The ulcerations in the study were occurring in
younger people than those who traditionally form the
1% of the population that experience leg ulceration.
Generally, this is a disease of old age and prevalence is
known to increase with age [68]. Whilst considered a
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ulceration before middle age. Work by Mackenzie et al.
[69] identified that in a sample of 118 patients with leg
ulceration, 46% had had developed ulceration before the
age of 50 years and were more likely to be male and
obese and to have a history of DVT and/or long bone
fracture. In mainstream studies of leg ulceration, it is
possible that injecting drug use is not considered as a
risk factor, especially if illicit use is hidden for example
in femoral injectors [70].
However, if younger people are increasingly experien-
cing leg ulceration, then the impact on health services
will be pronounced as recurrence occurs and as sufferers
age. Leg ulceration is end-stage venous disease [34] and
a chronic recurrent condition which is costly, not just in
terms of treatment but long-term prevention of recur-
rence and also in terms of human suffering [71]. The ul-
cers can be painful, malodorous and debilitating, badly
impacting on quality of life and costly to treat [72-74].
The impact on younger people may arguably be more
severe, preventing normal activities and possibly even
employment, and the ulceration may affect lives long
after drug use has ceased [75].
Treatment for venous ulcers in a more elderly po-
pulation consists of regular and frequent intervention,
usually with specialised compression therapy requiring
expert nursing staff and considerable time to achieve
healing. Generally, compression bandaging is followed
with long-term compression hosiery. Frequent appoint-
ments for treatment and long-term follow-up can be
challenging to achieve amongst a drug-using population
with chaotic lives who often have unstable accommoda-
tion arrangements, and there are no specific guidelines
to help practitioners manage this particular population.
Of course, the life expectancy of an injecting drug user
may be reduced, and therefore, the figures for long-term
injectors and older injectors in this study need to be
interpreted with caution due to reduced life span and
bias as a result of early death [76].
Within the general population, women tend to develop
leg ulceration more commonly than men [77,75], and this
increased prevalence is borne out within this study. It has
been suggested, although not conclusively, that this is due
to hormonal differences or longevity [78]. In drug injec-
tors, it has been suggested that women’s veins become
damaged and incompetent quicker than men as they tend
to be smaller and thinner walled [79]. It may also be that
women may tend to be more determined to hide the vis-
ual evidence of injecting and opt to inject in the groin
which impacts on disease processes in the lower leg [6].
Femoral injecting may increase the risk of deep vein
thrombosis due to repeated puncture, scarring and nar-
rowing of the femoral vein [32], and one of the com-
plications may be distal venous disease, including legulceration. In Glasgow, femoral injecting is relatively
common and the link between using this site and the high
rate of leg ulceration is worth exploring in the future.
Conclusion
This original paper reports on a unique empirical study
to determine the prevalence of skin problems and leg ul-
ceration in a sample of intravenous drug users. This is
the first paper that the authors are aware of that sets out
to carefully define skin lesions caused by injecting and
quantify these within a sample.
This study demonstrates that skin problems are a sig-
nificant, widespread issue for young injecting drug users.
It has revealed a high prevalence rate of leg ulceration
that is alarming. As leg ulceration is considered an end-
stage venous disease, it is reasonable to expect that as
intravenous drug users age, they will create a significant
proportion of patients requiring lower limb care. We
know leg ulcer care is costly [73], and the public health
implications of these chronic open wounds, which can
create dependent individuals with pain and impaired
mobility, are significant. Further studies are required to
examine the risk factors and the role of specific harm re-
duction activities such as dispensing of alcohol wipes for
skin cleansing and distribution and use of sterile equip-
ment, together with a closer examination of injecting
techniques such as licking of needles, flushing and use
of particular sites directly linked to skin problems, in
more depth.
Harm reduction initiatives have recently focused on
reducing the spread of blood-borne viruses but have
failed to address the direct harm as a consequence of
injecting. Raising awareness of wounds and skin break-
down in injecting drug users and health professionals
may help with earlier detection and intervention to com-
bat more serious disease or the development of more life-
threatening complications.
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